Attached files
file | filename |
---|---|
EX-99.2 - EX-99.2 - Intersect ENT, Inc. | d676868dex992.htm |
EX-99.1 - EX-99.1 - Intersect ENT, Inc. | d676868dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2019
Intersect ENT, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-36545 | 20-0280837 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Intersect ENT, Inc.
1555 Adams Drive
Menlo Park, California 94025
(Address of principal executive offices, including zip code)
(650) 641-2100
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On January 7, 2019, Intersect ENT, Inc. (the Company) issued a press release announcing its preliminary expectations of revenue for the fourth quarter of 2018 and the year ended December 31, 2018 as well as revenue guidance for the first quarter of 2019 and the year ending December 31, 2019. A copy of the Company press release is furnished and attached as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure
Members of the Companys management team expect to make a presentation regarding the Company (the Presentation) to investors and analysts and to meet with investors and analysts at the J.P. Morgan Annual Healthcare Conference between January 7, 2019 and January 10, 2019 to discuss the Presentation. A copy of the Presentation is furnished and attached as Exhibit 99.2.
The information in this Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K are being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 as amended (Exchange Act), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (Securities Act). The information in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 shall not be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
Description | |
99.1 | Press release entitled Intersect ENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue dated January 7, 2019. | |
99.2 | Presentation dated January 2019. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Intersect ENT, Inc. | ||||||
Dated: January 7, 2019 | ||||||
By: | /s/ Jeryl L. Hilleman | |||||
Jeryl L. Hilleman | ||||||
Chief Financial Officer |